Amgen to Report Q1 Earnings: Can It Keep the Beat Streak Alive?
Amgen heads into Q1 earnings with growth from key drugs offset by pricing pressure, patent losses, and biosimilar competition.
Open original sourceLoading market dashboard
Amgen heads into Q1 earnings with growth from key drugs offset by pricing pressure, patent losses, and biosimilar competition.
Open original source